

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 4

**Complete if Known**

Application Number

Filing Date

Even Date Herewith

First Named Inventor

David WALLACH

Group Art Unit

1642

Examiner Name

Attorney Docket Number

WALLACH=26A

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-6,326,354 B1	12-04-2001	Gross et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AB	WO 93/16178 A2	08-19-1993	USG DOHHS		
	AC	WO 97/48797 A1	12-24-1997	Genzyme Corp.		
	AD	WO 98/33883 A1	08-06-1998	Tularik, Inc		
	AE	WO 99/61626 A2	12-02-1999	Incyte Pharmaceuticals, Inc.		
	AF	WO 00/29674 A2	05-25-2000	Incyte Pharmaceuticals, Inc.		

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 4

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Even Date Herewith

David WALLACH

1642

Attorney Docket Number

WALLACH=26A

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AG	Bertin et al, "Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis", <u>Proc Natl Acad Sci</u> 94(4):1172-1176 (1997)	
	AH	Bowie et al, "Deciphering the message in protein sequences: tolerance to amino acid substitutions", <u>Science</u> 247(4948):1306-1310 (1990)	
	AI	Burgess et al, "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue" <u>J Cell Biol</u> 111(5 Pt 1):2129-2138 (1990)	
	AJ	Chou et al, "Prediction of the tertiary structure and substrate binding site of caspase-8" <u>FEBS Lett</u> 419(1):49-54 (1997)	
	AK	Frank AW, "Synthesis and properties of N-, O-, and S-phospho derivatives of amino acids, peptides, and proteins", <u>CRC Crit Rev Biochem</u> 16(1):51-101 (1984)	
	AL	GIBSON et al, "Homology between two EBV early genes and HSV ribonucleotide reductase and 38K genes", <u>Nucleic Acids Res</u> 12(12):5087-5099 (1984)	
	AM	HAN et al, "MRIT, a novel death-effector domain-containing protein, interacts with caspases and BelX <sub>1</sub> and initiates cell death", <u>Proc Natl Acad Sci</u> 94(21):11333-11338 (1997)	
	AN	Hu et al, "A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis", <u>J Biol Chem</u> 272(15):9621-9624 (1997)	
	AO	IIZUKA et al, "Enhanced expression of nucleobindin in lymphatic organs of lupus-prone mice", <u>Lupus</u> 6(4):365-370 (1997)	
	AP	ISHIKAWA et al, "Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro", <u>DNA Res</u> 4(5):307-313 (1997)	
	AQ	ISHIKAWA et al, "Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro", <u>DNA Res</u> 5(3):169-176 (1998)	
	AR	KAMADA et al, "A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin", <u>Proc Natl Acad Sci USA</u> 95(15):8532-8537 (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 4

**Complete if Known**

Application Number

Filing Date

Even Date Herewith

First Named Inventor

David WALLACH

Group Art Unit

1642

Examiner Name

Attorney Docket Number

WALLACH=26A

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AS	KAMINE et al, "Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator", <u>Virology</u> 216(2):357-366 (1996)	
	AT	KOSEKI et al., "ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases", <u>Proc Natl Acad Sci</u> 95(9):5156-5160 (1998)	
	AU	LAZAR et al, "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities", <u>Mol Cell Biol</u> 8(3):1247-1252 (1988)	
	AV	MEDEMA et al "FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)", <u>EMBO J</u> 16(10):2794-2804 (1997)	
	AW	MEDINA et al, "Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway", <u>Cancer Res</u> 57(17):3697-3707 (1997)	
	AX	MIURA et al, "Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure", <u>Biochem Biophys Res Commun</u> 187(1):375-380 (1992)	
	AY	MIURA et al, JP 06 025292, "Protein and its Gene" (February 1, 1994) Abstract Only (Database WPI: Section Ch, Week 199410 (Derwent Publications))	
	AZ	MUZIO et al, "FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens", <u>J Biol Chem</u> 272(5):2952-2956 (1997)	
	BA	SCAFFIDI et al "FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b, <u>J Biol Chem</u> 272(43):26953-26958 (1997)	
	BB	SCANLAN et al, "Characterization of human colon cancer antigens recognized by autologous antibodies", <u>Intl J Cancer</u> 76(5):652-658 (1998)	
	BC	TAKAHASHI et al, "Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CcrA-sensitive caspase-8", <u>Oncogene</u> 14(23):2741-2752 (1997)	
	BD	WRIGHT et al, "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts", <u>Exp Cell Res</u> 222(1):54-60 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Sheet	4	of	4	Application Number	
				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	1642
				Examiner Name	
				Attorney Docket Number	WALLACH=26A

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BE	Accession V01555, Farrell P, "Epstein-Barr virus (EBV) genome, strain 895-8" (December 6, 1983) (GENEMBL 'Online!')	
	BI	Accession C18037, Fujiwara T, "Human placenta cDNA 5'-end GEN-556E08" (October 4, 1996) (GENEMBL 'Online!')	
	BG	Accession H23509, Hillier et al, "ym53a01.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:51785 3' similar to ti gb:M64992 proteasome component C2 (human), mRNA sequence" (July 8, 1995) (GENEMBL 'Online!')	
	BJ	Accession AA608733, Hillier et al, "ae56f06.s1 Stratagene lung carcinoma 937218 homo sapiens cDNA clone IMAGE:950915 3' similar to TR:61224066 ORF2: Function unknown" (October 1, 1997) (GENEMBL 'Online!')	
	BF	Accession M96824, Miura et al, "Human nucleobindin precursor" (November 19, 1992) (GENEMBL 'Online!')	
	BK	Accession AB006626, O'Hara et al, "Homo sapiens mRNA for KIAA0288 protein, partial cds" (October 31, 1997) (GENEMBL 'Online!')	
	BL	Accession AB007870, O'Hara O, "Homo sapiens KIAA0419 mRNA complete cds" (December 5, 1997) (GENEMBL 'Online!')	
	BN	Accession AB014515, O'Hara et al, "Homo sapiens mRNA for KIAA0615 protein, complete cds" (July 15, 1998) (GENEMBL 'Online!')	
	BH	Accession U49973, Robertson HM, "ORF2 associated to human trigger 1 transposable element" (March 14, 1996) (GENEMBL 'Online!')	
	BP	Accession U67734, Sheridan et al, "Human cPLA2 interacting protein mRNA, complete cds" (January 6, 1999) (GENEMBL 'Online!')	
	BM	Accession AA746639: Strausberg R, "nx27c04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone IMAGE:1257318 3' similar to WP:F59B2.3 CE00231 N-acetyl-glucosamine-6-phosphate deacetylase, mRNA sequence" (January 19, 1998) (GENEMBL 'Online!')	
	BO	Accession AC004466: Worley et al, "Homo sapiens 12q13.1 PAC RPCI5-1057120 (Roswell Park Cancer Institute Human PAC library), Version AC004466.1; GI:3617739; September 17, 1998 (NCBI)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.